Stay updated with breaking news from Garry Menzel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelinPreclinical
CAMBRIDGE, Mass., May 11, 2023 -- TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors,... | May 11, 2023
Operator: Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.
Adaptimmune and TCR²'s new cell therapy company could gain the first approval for an engineered TCR T-cell therapy for a solid tumour.